To ascertain if CCR1-blocking BX471 can reverse the neurodegenerative process, we sought to assess the expression of α-synuclein, as this protein accumulation in the substantia nigra is a PD crucial marker. This evidence concerns the gene CCR1 and Parkinson disease.